Health is our mission

Press releases

 

 

Reagila named Medicine of the Year25612020.00000000000<p>​<strong>Richter's atypical antipsychotic, Reagila, containing the active ingredient cariprazine, was awarded the prize of Medicine of the Year 2019 by the Hungarian Society for Experimental and Clinical Pharmacology (MFT). Each year, this prestigious award recognises the most advanced and effective products that have made a significant breakthrough in the treatment of a disease. The award was presented to Erik Bogsch, Chairman of the Board of Gedeon Richter Plc by Dr Péter Ferdinandy, President of MFT.</strong></p>2020-06-10T22:00:00Z6/12/2020 8:03:35 AM1874http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter’s response to COVID-19 pandemic2083<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2020.00000000000<p>​In its endeavour to keep its patients, employees, investors and the society at large informed about recent developments the Management of Richter as advised by its &quot;Pandemic Response Team&quot; makes the following public statement.</p>2020-04-21T22:00:00Z4/22/2020 6:31:20 AM1705http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter supports Hungarian hospitals with HUF 140 million2080<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2020.00000000000<p style="text-align&#58;justify;">​In view of the extraordinary situation caused by the coronavirus epidemic and the challenges facing Hungarian healthcare institutions, Gedeon Richter Plc. has decided to offer a financial aid of HUF 2 million to each of the hospitals and clinics that have participated in its Health City programme. Over the past 10 years, Richter has supported these health care institutions with donations totalling HUF 380 million, now this amount is being increased by an additional HUF 140 million. The 70 Hungarian hospitals and clinics will receive Richter's donation of HUF 140 million as emergency financial assistance, readily available and free to use.</p>2020-04-19T22:00:00Z4/20/2020 9:21:32 AM155http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Members of Richter’s governing bodies offer their one-month remuneration to the National Ambulance Service in Hungary2065<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2020.00000000000<p>​All members of the Board of Directors and the Supervisory Board of Gedeon Richter Plc donated their one-month remuneration to the doctors and paramedics of the National Ambulance Service (OMSZ), which plays a key role in the fight against the coronavirus epidemic. The donation of a total of HUF 6 million has been transferred to the association that supports the recreation of the Service's employees.</p>2020-04-13T22:00:00Z4/14/2020 10:24:18 AM227http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
John Macor, PhD is Awarded the 2020 IUPAC-Richter Prize2283<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2020.00000000000<p>​​​​The 2020 IUPAC-Richter Prize in Medicinal Chemistry has been awarded to John Macor, PhD, Global Head Integrated Drug Discovery, Sanofi</p>2020-01-21T23:00:00Z1/22/2020 10:16:18 AM80http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/Forms/AllItems.aspxhtmlFalseaspx
A twenty-five-year long success story: Richter shares were first listed 25 years ago2153<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.00000000000<p>​<strong>Gedeon Richter Plc's shares were listed on the Budapest Stock Exchange twenty-five years ago, on 9 November 1994, which was commemorated by a solemn ring of the bell at the stock exchange marking the start of trading.</strong><strong> Since then, the price of the company's shares has risen by forty-four times, which is a unique success story for both the Hungarian stock exchange and the Hungarian national economy. Over the past two and a half decades, the company has grown into an innovative multinational company that, by making history in its industry, was able to introduce a proprietary product to the US market through its partner, which has since been extremely successful. In addition, the company has become a global player in the field of women's healthcare and recently entered the fastest growing segment of the pharmaceutical industry, the biologics market, with its proprietary product.</strong></p>2019-11-21T23:00:00Z11/22/2019 11:54:16 AM760http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Molecular Biology Laboratory inaugurated in the Hungarian city of Debrecen712<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.00000000000<p>​<span lang="EN-GB"><strong>Lajos Kósa, Hungary’s Minister without Portfolio, responsible for the development of Cities of County Rank, Dr László Papp, Mayor of Debrecen, Erik Bogsch, Gedeon Richter Plc’s Chairman and Gábor Orbán, Gedeon Richter Plc’s CEO inaugurated Richter’s new Molecular Biology Laboratory at a ceremony held in the Hungarian city of Debrecen. The facility was built with a total budget of HUF 4.89 billion as part of a joint consortium tender entitled “Innovative pharmaceutical research and development project to improve competitiveness in the market”. The total investment cost of the laboratory infrastructure and technological equipment (as a part of the project) was close to HUF 1.7 billion, of which HUF 713 million was funded by the awarded aid. </strong></span></p>2018-03-28T22:00:00Z3/29/2018 2:09:12 PM7011http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Gedeon Richter Plc’s antipsychotic drug wins the 2017 Innovation Grand Prize275<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" /><p><strong>​</strong><span lang="EN-GB"><strong>The Hungarian Innovation Foundation has awarded Gedeon Richter Plc the Innovation Grand Prize for its tender proposal entitled “Cariprazine</strong></span><span lang="EN-GB"><strong> (Vraylar®/Reagila®), a new original Hungarian drug on the global market”. The Innovation Grand Prize was presented to Gedeon Richter Plc’s Chairman Erik Bogsch by János Latorcai, Vice Speaker of the Hungarian National Assembly and József Pálinkás, President of the National Research, Development and Innovation Office. </strong></span></p>2018-03-27T22:00:00Z3/28/2018 11:51:37 AM1659http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Peter D.J. Grootenhuis, Ph.D. is Awarded the 2018 IUPAC-Richter Prize2372<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.00000000000​<span lang="EN-GB"><strong>The 2018 IUPAC-Richter Prize in Medicinal Chemistry has been awarded to Peter D.J. Grootenhuis. </strong></span><br><br>2018-01-25T23:00:00Z1/26/2018 1:00:32 PM2349http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Allergan and Richter Announce Positive Topline Results from Phase III Study of Cariprazine for the Treatment of Bipolar I Depression414<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.00000000000<p>​<span lang="EN-US" style="line-height&#58;115%;font-family&#58;&quot;arial&quot;,&quot;sans-serif&quot;;font-size&#58;11pt;"><font color="#000000" face="Arial">Allergan plc (NYSE&#58; AGN), a leading global pharmaceutical company, and Gedeon Richter Plc., today announced positive topline results for a phase III study of cariprazine for the treatment of adults with major depressive episodes associated with bipolar I disorder (bipolar I depression). This is the second positive pivotal trial of cariprazine for this investigational use. </font></span></p>2017-12-17T23:00:00Z12/18/2017 1:12:04 PM2184http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx